Back to results
US 2003/0119058 A1Published application
Method of assaying type III collagen degradation
AssigneeOsteometer A/S
InventorsPer Qvist, Martin Bonde
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOsteometer A/S
InventorsPer Qvist, Martin Bonde
Estimating the term…
A method of assaying collagen fragments in body fluids, including bringing a sample of body fluid in contact with at least one immunological binding partner for the collagen fragments, said binding partner being immunoreactive with synthetic peptides, the sequences of which are essentially derived from collagen and containing potential sites for cross-linking. The immunological binding partners are incorporated, either as whole antibodies or as immunologically active fragments thereof, in an assay for quantitative determination of collagen fragments in the sample. In addition to being contacted with the immunological binding partner(s), the sample may be brought into direct contact with the corresponding synthetic peptide. The invention further comprises a test kit and specific means for carrying out the method. The structure of specific peptides is also described.
A method of determining collagen fragments in a body fluid, wherein a sample of said body fluid is brought into contact with at least one immunological binding partner for the collagen fragments, said binding partner being an antibody immunoreactive with synthetic peptides the sequences of which are essentially derived from collagen and containing potential sites for cross-linking, said immunological binding partners being incorporated, either as whole antibodies or as immunologically active fragments thereof, in an assay for quantitative determination of collagen fragments in the sample.
An immunological binding partner raised by immunization with synthetic peptides selected from the group consisting of sequences derived from the sequence of human collagen type I and consisting essentially of one of the following structures
A test kit for quantitating the amount of collagen fragments in a body fluid, said kit comprising at least one immunological binding partner immunoreactive with a synthetic peptide having a sequence essentially derived from collagen and containing one or more potential sites for cross-linking.
A method of diagnosing the presence of disorders associated with the metabolism of collagen in a patient, said method comprising the steps of:
A method for determining whether a susceptible subject is suffering from collagen degradation comprising the steps of:
A method for determining the presence of collagen degradation products in a body fluid comprising the steps of:
Dependencies are inferred from the claim text.